Orphan Drug Makers Get Selected Tax Breaks As China Turns To Access
Executive Summary
Following anticancer drugs, rare disease treatments become the latest products in China’s to get value added tax reductions. Orphan drug makers can breath easier, but much more is needed, industry insiders say.